I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231 on this 7th day of August, 2002.

(Signature of person mailing)
Pamela Ancona

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Y. Hashizume, et al.

APPLICATION NO.: 09/977,621

Examiner: Not Assigned

FILING DATE:

October 15, 2001

Group Art Unit: Not Assigned

TITLE:

ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS

Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the reference cited by the applicant(s), a copy of which is enclosed.

The Examiner is requested to consider carefully the complete text of this reference in connection with the examination of the above-identified application in accord with 37 C.F.R. presently claimed is neither anticipated nor rendered obvious by the foregoing reference.

It is requested that the reference listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

Date:

august 7, 2002

Respectfully submitted,

Pamela C. Ancona Attorney for Applicant(s)

Reg. No. 41,494

Pfizer, Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5612 (212) 733-6031